Assembly Biosciences (NASDAQ:ASMB) Earning Somewhat Positive Press Coverage, Report Finds
Media stories about Assembly Biosciences (NASDAQ:ASMB) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Assembly Biosciences earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near future.
Assembly Biosciences (NASDAQ:ASMB) opened at 22.36 on Friday. The firm’s 50-day moving average is $23.33 and its 200-day moving average is $21.01. Assembly Biosciences has a 52-week low of $5.15 and a 52-week high of $28.24. The company’s market cap is $387.86 million.
Separately, Chardan Capital began coverage on shares of Assembly Biosciences in a research report on Tuesday, May 30th. They issued a “buy” rating and a $35.00 price target on the stock.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.